PTC Therapeutics Inc PTCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
-
PTC Therapeutics to Participate in Upcoming Investor Conferences
-
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
-
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
-
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
-
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
-
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Trading Information
- Previous Close Price
- $64.13
- Day Range
- $62.80–65.40
- 52-Week Range
- $61.23–90.87
- Bid/Ask
- $60.00 / $75.00
- Shares Outstanding
- 83.46M
- Market Cap
- $5.30B
- Volume/Avg
- 895,554 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 8.13
- Price/Sales
- 5.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 991
- Website
- https://www.ptcbio.com
Valuation
|
Metric
|
PTCT
|
|---|---|
Price/Earnings (Normalized) | 8.13 |
Price/Book Value | — |
Price/Sales | 5.78 |
Price/Cash Flow | 91.48 |
Price/Earnings
PTCT
Financial Strength
|
Metric
|
PTCT
|
|---|---|
Quick Ratio | 3.20 |
Current Ratio | 3.39 |
Interest Coverage | 0.64 |
Quick Ratio
PTCT
Profitability
|
Metric
|
PTCT
|
|---|---|
Return on Assets (Normalized) | 0.38% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 21.35% |
Return on Assets
PTCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!Yhc<Q | LOCK|@%dd$ | $128B | |||
| Moderna Inc
MRNA
| LOCK|lR&mz^Z | LOCK|QX@ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|zNfLdS | LOCK|&zvM | $76B | |||
| argenx SE ADR
ARGX
| LOCK|?@WNKS | LOCK|$# | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Xn?!YW | LOCK|jr | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vzmf$gX | LOCK|!Q&R | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@FzP@>D$ | LOCK|<SB$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|XcFk^h& | LOCK|jjS | $24B | |||
| Incyte Corp
INCY
| LOCK|^y<Bm>@ | LOCK|@Y | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?VRD^TB | LOCK|VR | $15B |
United States